Recent studies reported that upregulation of ECT2 predicted adverse clinical outcomes and increased 5-fluorouracil (5-Fu) resistance in GC patients29, and was associated with transcriptional program of cancer stem cells (CSCs)30. This evidence concerns the gene ECT2 and cancer.